Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrea Freeman
Observed names:
A Freeman,
A. Freeman
Observed institutions:
Brigham and Women's Hospital,
Mayo Clinic,
Harvard University,
Moffitt Cancer Center,
Saint Vincent's Catholic Medical Center,
Dana-Farber Cancer Institute,
Dana-Farber Brigham Cancer Center,
Celgene (United States)
show all 8
OpenAlex ID:
A5047797229
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
2002
·
Paul G. Richardson
, Robert L. Schlossman
, et al.
·
Blood
·
805
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
2006
·
Paul G. Richardson
, Emily Blood
, et al.
·
Blood
·
523
PDF
T-cell–depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect
2001
·
Edwin Alyea
, Edie Weller
, et al.
·
Blood
·
204
Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity
2004
·
Paul Richardson
, Robert Schlossman
, et al.
·
Mayo Clinic Proceedings
·
127
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma
1993
·
KC Anderson
, J Andersen
, et al.
·
Blood
·
100
PDF
CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission
1997
·
Robert J. Soiffer
, Diane Fairclough
, et al.
·
Blood
·
87
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect
2003
·
E Alyea
, E Weller
, et al.
·
Bone Marrow Transplantation
·
73
Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).
2004
·
Paul G. Richardson
, Asher Chanan-Khan
, et al.
·
Blood
·
58
CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma
1998
·
RJ Soiffer
, AS Freedman
, et al.
·
Bone Marrow Transplantation
·
36
CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
1997
·
R J Soiffer
, P Mauch
, et al.
·
PubMed
·
34
Monoclonal Antibody-Purged Bone Marrow Transplantation Therapy for Multiple Myeloma
1995
·
Michael V. Seiden
, Robert Schlossman
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
32
A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).
2001
·
PG Richardson
, RL Schlossman
, et al.
·
Blood
·
25
A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.
2005
·
Paul Richardson
, A. Chanan-Khan
, et al.
·
Blood
·
23
In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation.
1997
·
I J Webb
, R J Soiffer
, et al.
·
PubMed
·
14
High-dose cytoreductive therapy with autologous bone marrow transplantation in advanced malignancies.
1983
·
A Barbasch
, D J Higby
, et al.
·
PubMed
·
12
Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).
2004
·
Paul Richardson
, Robert L. Schlossman
, et al.
·
Blood
·
8
Predictors of high yield and purity of CD34+ cell-selected PBPC, collected from patients with multiple myeloma
1999
·
I.J. Webb
, R.L. Schlossman
, et al.
·
Cytotherapy
·
1
Myeloma Resistance and is Well Tolerated in Patients with Relapse Multiple Immunomodulatory Derivative of Thalidomide CC-5013 Overcomes Drug
2013
·
Kathe Balinski
, Jerome B. Zeldis
, et al.
Show more works
View as search
Works count:
18
Citation count:
2,162
H-index:
14
I10-index:
15
Year
Topic
Type
